PhRMA backs FDA plans for biosimilar fees discussion
US drug industry group PhRMA has backed FDA plans to discuss fees for biosimilars with pharmaceutical manufacturers.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs